154 related articles for article (PubMed ID: 31766770)
1. LABAs and p38MAPK Inhibitors Reverse the Corticosteroid-Insensitivity of IL-8 in Airway Smooth Muscle Cells of COPD.
Knobloch J; Jungck D; Kronsbein J; Stoelben E; Ito K; Koch A
J Clin Med; 2019 Nov; 8(12):. PubMed ID: 31766770
[TBL] [Abstract][Full Text] [Related]
2. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
[TBL] [Abstract][Full Text] [Related]
3. Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review.
Solidoro P; Patrucco F; Bagnasco D
Expert Rev Respir Med; 2019 Nov; 13(11):1087-1094. PubMed ID: 31498714
[No Abstract] [Full Text] [Related]
4. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD.
Hanania NA
Pulm Pharmacol Ther; 2008; 21(3):540-50. PubMed ID: 18280761
[TBL] [Abstract][Full Text] [Related]
5. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
Spencer S; Evans DJ; Karner C; Cates CJ
Cochrane Database Syst Rev; 2011 Oct; (10):CD007033. PubMed ID: 21975759
[TBL] [Abstract][Full Text] [Related]
6. Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease.
Nannini L; Lasserson TJ; Poole P
Cochrane Database Syst Rev; 2003; (4):CD003794. PubMed ID: 14583994
[TBL] [Abstract][Full Text] [Related]
7. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
[TBL] [Abstract][Full Text] [Related]
8. Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease.
Nannini L; Cates CJ; Lasserson TJ; Poole P
Cochrane Database Syst Rev; 2004; (3):CD003794. PubMed ID: 15266502
[TBL] [Abstract][Full Text] [Related]
9. Fluticasone, but not salmeterol, reduces cigarette smoke-induced production of interleukin-8 in human airway smooth muscle.
Oltmanns U; Walters M; Sukkar M; Xie S; Issa R; Mitchell J; Johnson M; Chung KF
Pulm Pharmacol Ther; 2008; 21(2):292-7. PubMed ID: 17692547
[TBL] [Abstract][Full Text] [Related]
10. Long-acting β2-agonists increase fluticasone propionate-induced mitogen-activated protein kinase phosphatase 1 (MKP-1) in airway smooth muscle cells.
Manetsch M; Rahman MM; Patel BS; Ramsay EE; Rumzhum NN; Alkhouri H; Ge Q; Ammit AJ
PLoS One; 2013; 8(3):e59635. PubMed ID: 23533638
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.
Perrone V; Sangiorgi D; Buda S; Degli Esposti L
Int J Chron Obstruct Pulmon Dis; 2016; 11():2749-2755. PubMed ID: 27853362
[TBL] [Abstract][Full Text] [Related]
12. Benefit-risk assessment of long-acting beta2-agonists in asthma.
Jackson CM; Lipworth B
Drug Saf; 2004; 27(4):243-70. PubMed ID: 15003036
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting β2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment.
Pelaia G; Muzzio CC; Vatrella A; Maselli R; Magnoni MS; Rizzi A
Expert Opin Pharmacother; 2015; 16(13):2009-21. PubMed ID: 26194120
[TBL] [Abstract][Full Text] [Related]
14. Acute effects of salmeterol and fluticasone propionate alone and in combination on airway blood flow in patients with asthma.
Mendes ES; Rebolledo P; Wanner A
Chest; 2012 May; 141(5):1184-1189. PubMed ID: 21980058
[TBL] [Abstract][Full Text] [Related]
15. Clinical safety of long-acting beta2-agonist and inhaled corticosteroid combination therapy in COPD.
Decramer M; Ferguson G
COPD; 2006 Aug; 3(3):163-71. PubMed ID: 17240618
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol impairs the release of steroid-resistant inflammatory cytokines from human airway smooth muscle cells in chronic obstructive pulmonary disease.
Knobloch J; Sibbing B; Jungck D; Lin Y; Urban K; Stoelben E; Strauch J; Koch A
J Pharmacol Exp Ther; 2010 Dec; 335(3):788-98. PubMed ID: 20801891
[TBL] [Abstract][Full Text] [Related]
17. Breathomics for Assessing the Effects of Treatment and Withdrawal With Inhaled Beclomethasone/Formoterol in Patients With COPD.
Montuschi P; Santini G; Mores N; Vignoli A; Macagno F; Shoreh R; Tenori L; Zini G; Fuso L; Mondino C; Di Natale C; D'Amico A; Luchinat C; Barnes PJ; Higenbottam T
Front Pharmacol; 2018; 9():258. PubMed ID: 29719507
[No Abstract] [Full Text] [Related]
18. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD.
Fuso L; Mores N; Valente S; Malerba M; Montuschi P
Curr Med Chem; 2013; 20(12):1477-95. PubMed ID: 23409722
[TBL] [Abstract][Full Text] [Related]
19. p38 mitogen-activated protein kinase-γ inhibition by long-acting β2 adrenergic agonists reversed steroid insensitivity in severe asthma.
Mercado N; To Y; Kobayashi Y; Adcock IM; Barnes PJ; Ito K
Mol Pharmacol; 2011 Dec; 80(6):1128-35. PubMed ID: 21917909
[TBL] [Abstract][Full Text] [Related]
20. Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease.
Fenton C; Keating GM
Drugs; 2004; 64(17):1975-96. PubMed ID: 15329047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
